Synthesis and biological evaluation of α-santonin derivatives as anti-hepatoma agents. 2018

Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
School of Pharmacy, Second Military Medical University, Shanghai 200433, China; State Key Laboratory of Innovative Natural Medicine and TCM Injections, Jiangxi Qingfeng Pharmaceutical Co., Ltd, Ganzhou 341000, Jiangxi, China.

A series of α-santonin-derived compounds as potentially anti-hepatoma agents were designed and synthesized in an effort to find novel therapeutic agents. Among them, derivative 5h was more potent than the positive control 5-fluorouracil (5-Fu) on HepG-2, QGY-7703 and SMMC-7721 with IC50 values of 7.51, 3.06 and 4.08 μM, respectively. The structure-activity relationships (SARs) of these derivatives were discussed. In addition, flow cytometry and western blot assay revealed that the derivatives induced hepatoma cells apoptosis by facilitating apoptosis-related proteins expressions. Our findings suggested that these α-santonin-derived analogues hold promise as chemotherapeutic agents for the treatment of human hepatocellular cancer.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012500 Santonin Anthelmintic isolated from the dried unexpanded flower heads of Artemisia maritima and other species of Artemisia found principally in Russian and Chinese Turkestan and the Southern Ural region. (From Merck, 11th ed.)
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
December 2010, European journal of medicinal chemistry,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
November 2013, European journal of medicinal chemistry,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
April 2021, RSC advances,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
April 2024, Bioorganic chemistry,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
April 2012, Molecules (Basel, Switzerland),
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
September 2009, Bioorganic & medicinal chemistry letters,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
October 2018, International journal of molecular sciences,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
January 2014, Medicinal chemistry (Shariqah (United Arab Emirates)),
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
June 2023, RSC advances,
Hao Chen, and Xiao Yang, and Zongmin Yu, and Ziying Cheng, and Hu Yuan, and Zeng Zhao, and Guozhen Wu, and Ning Xie, and Xing Yuan, and Qingyan Sun, and Weidong Zhang
September 2016, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!